Trials / Completed
CompletedNCT00161954
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 16 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL using a rapid immunization schedule (2 vaccinations administered 12 +/- 2 days apart.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) |
Timeline
- Start date
- 2004-03-01
- Completion
- 2004-05-01
- First posted
- 2005-09-13
- Last updated
- 2015-05-21
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00161954. Inclusion in this directory is not an endorsement.